Cargando…

Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients

BACKGROUND AND OBJECTIVE: The direct-acting antiviral agents (DAAs) antiviral therapy has drastically improved the prognosis of hepatitis C virus (HCV) patients. However, the viral drug resistance-associated variants (RAVs) can limit the efficacy of DAAs. For the HCV-6a is not the predominant preval...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zhanyi, Liu, Ying, Zhang, Ying, Shao, Xiaoqiong, Luo, Qiumin, Guo, Xiaoyan, Lin, Guoli, Cai, Qingxian, Zhao, Zhixin, Chong, Yutian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5661091/
https://www.ncbi.nlm.nih.gov/pubmed/29164151
http://dx.doi.org/10.1155/2017/9849823
_version_ 1783274415791800320
author Li, Zhanyi
Liu, Ying
Zhang, Ying
Shao, Xiaoqiong
Luo, Qiumin
Guo, Xiaoyan
Lin, Guoli
Cai, Qingxian
Zhao, Zhixin
Chong, Yutian
author_facet Li, Zhanyi
Liu, Ying
Zhang, Ying
Shao, Xiaoqiong
Luo, Qiumin
Guo, Xiaoyan
Lin, Guoli
Cai, Qingxian
Zhao, Zhixin
Chong, Yutian
author_sort Li, Zhanyi
collection PubMed
description BACKGROUND AND OBJECTIVE: The direct-acting antiviral agents (DAAs) antiviral therapy has drastically improved the prognosis of hepatitis C virus (HCV) patients. However, the viral drug resistance-associated variants (RAVs) can limit the efficacy of DAAs. For the HCV-6a is not the predominant prevalent genotype; the data on the prevalence of naturally occurring RAVs in it is scarce. Our study aims to assess the prevalence of RAVs in treatment-naive HCV-6a patients. METHODS: Nested PCR assays were performed on 95 HCV-6a patients to amplify HCV viral regions of NS3, NS5A, and NS5B. RESULTS: In NS3/4A region, we detected Q80K in 95.5% isolates (84/88) and D168E in 2.3% isolates (2/88). In NS5A region, we detected Q30R in 93.2% isolates (82/88), L31M in 4.6% isolates (4/88), and H58P in 6.8% isolates (6/88). In NS5B region, we detected A15G in 2.3% isolates (2/88), S96T in 1.1% isolates (1/88), and S282T in 20.7% isolates (17/88) and we detected I482L in 100% isolates (4/4), V494A in 50% isolates (2/4), and V499A in 100% isolates (4/4). CONCLUSIONS: RAVs to DAAs preexist in treatment-naive HCV-6a patients. Further studies should address the issue of the impact of RAVs in response to DAA therapies for HCV-6a patients.
format Online
Article
Text
id pubmed-5661091
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-56610912017-11-21 Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients Li, Zhanyi Liu, Ying Zhang, Ying Shao, Xiaoqiong Luo, Qiumin Guo, Xiaoyan Lin, Guoli Cai, Qingxian Zhao, Zhixin Chong, Yutian Biomed Res Int Research Article BACKGROUND AND OBJECTIVE: The direct-acting antiviral agents (DAAs) antiviral therapy has drastically improved the prognosis of hepatitis C virus (HCV) patients. However, the viral drug resistance-associated variants (RAVs) can limit the efficacy of DAAs. For the HCV-6a is not the predominant prevalent genotype; the data on the prevalence of naturally occurring RAVs in it is scarce. Our study aims to assess the prevalence of RAVs in treatment-naive HCV-6a patients. METHODS: Nested PCR assays were performed on 95 HCV-6a patients to amplify HCV viral regions of NS3, NS5A, and NS5B. RESULTS: In NS3/4A region, we detected Q80K in 95.5% isolates (84/88) and D168E in 2.3% isolates (2/88). In NS5A region, we detected Q30R in 93.2% isolates (82/88), L31M in 4.6% isolates (4/88), and H58P in 6.8% isolates (6/88). In NS5B region, we detected A15G in 2.3% isolates (2/88), S96T in 1.1% isolates (1/88), and S282T in 20.7% isolates (17/88) and we detected I482L in 100% isolates (4/4), V494A in 50% isolates (2/4), and V499A in 100% isolates (4/4). CONCLUSIONS: RAVs to DAAs preexist in treatment-naive HCV-6a patients. Further studies should address the issue of the impact of RAVs in response to DAA therapies for HCV-6a patients. Hindawi 2017 2017-10-15 /pmc/articles/PMC5661091/ /pubmed/29164151 http://dx.doi.org/10.1155/2017/9849823 Text en Copyright © 2017 Zhanyi Li et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Li, Zhanyi
Liu, Ying
Zhang, Ying
Shao, Xiaoqiong
Luo, Qiumin
Guo, Xiaoyan
Lin, Guoli
Cai, Qingxian
Zhao, Zhixin
Chong, Yutian
Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients
title Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients
title_full Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients
title_fullStr Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients
title_full_unstemmed Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients
title_short Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients
title_sort naturally occurring resistance-associated variants to hepatitis c virus direct-acting antiviral agents in treatment-naive hcv genotype 6a-infected patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5661091/
https://www.ncbi.nlm.nih.gov/pubmed/29164151
http://dx.doi.org/10.1155/2017/9849823
work_keys_str_mv AT lizhanyi naturallyoccurringresistanceassociatedvariantstohepatitiscvirusdirectactingantiviralagentsintreatmentnaivehcvgenotype6ainfectedpatients
AT liuying naturallyoccurringresistanceassociatedvariantstohepatitiscvirusdirectactingantiviralagentsintreatmentnaivehcvgenotype6ainfectedpatients
AT zhangying naturallyoccurringresistanceassociatedvariantstohepatitiscvirusdirectactingantiviralagentsintreatmentnaivehcvgenotype6ainfectedpatients
AT shaoxiaoqiong naturallyoccurringresistanceassociatedvariantstohepatitiscvirusdirectactingantiviralagentsintreatmentnaivehcvgenotype6ainfectedpatients
AT luoqiumin naturallyoccurringresistanceassociatedvariantstohepatitiscvirusdirectactingantiviralagentsintreatmentnaivehcvgenotype6ainfectedpatients
AT guoxiaoyan naturallyoccurringresistanceassociatedvariantstohepatitiscvirusdirectactingantiviralagentsintreatmentnaivehcvgenotype6ainfectedpatients
AT linguoli naturallyoccurringresistanceassociatedvariantstohepatitiscvirusdirectactingantiviralagentsintreatmentnaivehcvgenotype6ainfectedpatients
AT caiqingxian naturallyoccurringresistanceassociatedvariantstohepatitiscvirusdirectactingantiviralagentsintreatmentnaivehcvgenotype6ainfectedpatients
AT zhaozhixin naturallyoccurringresistanceassociatedvariantstohepatitiscvirusdirectactingantiviralagentsintreatmentnaivehcvgenotype6ainfectedpatients
AT chongyutian naturallyoccurringresistanceassociatedvariantstohepatitiscvirusdirectactingantiviralagentsintreatmentnaivehcvgenotype6ainfectedpatients